this paper determines the optimal radiation shield thicknesses for the patient treatment room. Since this is an experimental facility no moderator or reflector is considered in the bulk wall shield design. This w i l l allow the flexibility of using any postulated moderator/reflector design and assumes sufficient shielding even in the absence of a moderator/reflector. In addition the accelerator is assumed to be capable of producing 100 mA of 2.5 MeV proton beam current. The addition, of 1% and 2% ' OB (by weight) to the concrete is also investigated. The second part of this paper determines the radiation dose to the major organs of a patient during a treatment. Simulations use the MIRD 5 anthropomorphic phantom' to calculate organ doses from a 20 mA proton beam assuming various envisioned moderator/reflector in place. Doses are tabulated by component and for a given uniform 'OB loading in all organs. These are presented in Table 8 for a Be0 moederator and in Table 7 for an AI/AIF3 moderator. Dose estimates for different ' OB loadings may be scaled. 
Shielding of Treatment R o o m
Radiation shield walls will be necessary to reduce neutron and photon dose rates outside the patient treatment room to personnel working nearby. In this section we determine the necessary concrete shield thickness. All analyses are performed with the MCNP3 Monte Carlo radiation transport code. Flux-to-dose equivalent conversion factors are taken from Belog01-10~~. These conversion factors were calculated by Belogorlov by considering the energy deposition in an semi-infinite slab of tissue from monoenergetic neutron beams as a function of depth. These are shown in Table 1 .
The assumed layout of the patient treatment room is shown in Fig. 1 . All walls are assumed to be 480 cm from the target to the inside of the shield wall. All walls used is shown in Table 2 . The neutron spectrum from the 7Li(p,n) reaction is taken from a previous report1 for an incident 2.5 MeV proton beam of 100 mA. The current accelerator design is based on delivering at least 20 mA but possibly as high as 100 mA. Therefore the radiation shielding is based on a beam current of 100 mA. No moderator or reflector is assumed to be present, ie., the target is bare. This is to ensure that the shield design is independent of a particular moderator/reflector configuration.
This will allow for the flexibility of experimenting with various moderator/reflector designs and for neutron spectra measurements without the moderator/reflector.
Biological dose equivalents are computed by converting the neutron and gamma fluxes to dose equivalent at different depths in a single thick shield wall Le., one simulation is done and dose equivalent rates are examined at various depths as opposed to the more correct approach of doing seperate simulations for each thickness and tallying the dose equivalent rate immediately outside the shield wall. The effect of this is to increase the dose equivalent by including the contributions due to backscatter within the shield wall. This greatly reduces the number of simulations to be made and is estimated to increase the dose equivalant by no more than a factor of two. This is acceptable for radiation protection purposes and errs on the side on conservatism.
All neutron and photon scoring is done using the MCNP point detector tally. This is a biased tally whereby an estimate is made to the tally location of all interactions in the shield, wether or not the particle ever reaches the actual detector location. This is a very efficient technique for such deep penetration problems and results in good statistical accuracy.
The results for the front wall (with respect to the proton beam) are shown in moderator/reflector design is shown in Fig. 5'. A cutaway of the First, an estimate is made of the dose equivalent rate below the moderator/reflector assembly using the whole body dose conversion factors of Belogorlov* . This is done In order to calculate patient organ doses, the MIRD 5 anthropormorphic phantom6
is placed below the moderator/reflector assembly in the prone position as shown in for ' OB. The complete neutron source energy spectrum used has been described previously'. All doses and dose rates are normalized to a proton beam current of 20 mA. Elemental tissue and bone compositions used are shown in Table 4 .
As a first step we benchmark the phanton results with our previous results''.
In this work, the patient treatment planning software being developed at INEL, anthropomorphic phantom using MCNP and the INEL treatment software using human CT scans is quite good given the differences in calculational methods. ' Total dose equivalent rate (cGy-RBE-min-l per 20 mA) over treatment time.
Total dose equivalent (cGy-RBE per 20 mA) over treatment time. The estimated absorbed dose rates for select major organs are given in Table 6 for a Be0 moderator and Table 7 for an Al/AlF3 moderator. An arbitrary concentration of 10 mg of 'OB for 1 g of soft tissue (concentration = 10 ppm) is assumed for all organs for scaling purposes. The 'OB dose component may be scaled accordingly for actual measured/estimated uptake in each organ to determine the actual organ dose. Of particular concern may be the boron uptake in blood-filtering organs such as the kidneys and liver. In general, for uniform boron uptake, those organs closest to the head receive the largest absorbed dose equivalents. The dose can be seen to drop about a n order of magnitude from brain to lungs, and another order of magintude from lungs to testes. Dose equivalents are lowest for the kidneys as they receive the most shielding effect from the body.
As stated previously, the kerma factors used for all organs were the ICRU soft tissue kermas from ICRU 468. However, kerma factors for each specific organ are also available but were not used out of expediency. Total dose equivalent rate (cGy-RBE-min-' per 20 mA) over treatment time.
that additional optimization work should investigate the role of leakage radiation in tumor and normal tissue brain dose.
